Sonnet BioTherapeutics Holdings (SONN) has shared an announcement.
The Company has partnered with the Sarcoma Oncology Center to further the development of SON-1210—a promising new drug for solid tumor immunotherapy, focusing on pancreatic cancer. The drug, hailed for its preclinical success and lack of severe toxicity, will undergo a Phase 1/2a clinical study to assess its efficacy in combination with approved chemotherapy agents. This study underscores the Company’s commitment to addressing the urgent need for effective pancreatic cancer treatments, with forward-looking statements suggesting a positive outlook for its clinical and commercial potential.
For an in-depth examination of SONN stock, go to TipRanks’ Stock Analysis page.
